Continuous intravenous infusion (CIV) at 70 mg kg−1 of pinometostat in a rat xenograft model of MLL-rearranged leukaemia caused complete tumour regression after 14 days with no observed weight loss or toxicity.142 This route of administration was necessary for maintaining plasma levels of pinometostat at efficacious concentrations, due to its poor oral bioavailability and short half-life. This evidence concerns the gene KMT2A and leukemia.